» Articles » PMID: 29193284

Drug Burden Index to Define the Burden of Medicines in Older Adults with Intellectual Disabilities: An Observational Cross-sectional Study

Overview
Specialty Pharmacology
Date 2017 Dec 2
PMID 29193284
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: The drug burden index (DBI) is a dose-related measure of anticholinergic and sedative drug exposure. This cross-sectional study described DBI in older adults with intellectual disabilities (ID) and the most frequently reported therapeutic classes contributing to DBI and examined associations between higher DBI scores and potential adverse effects as well as physical function.

Methods: This study analysed data from Wave 2 (2013/2014) of the Intellectual Disability Supplement to the Irish Longitudinal Study on Ageing (IDS-TILDA), a representative study on the ageing of people with ID in Ireland. Self- and objectively-reported data were collected on medication use and physical health, including health conditions. The Barthel index was the physical function measure.

Results: The study examined 677 individuals with ID, of whom 644 (95.1%) reported taking medication and 78.6% (n = 532) were exposed to medication with anticholinergic and/or sedative activity. 54.2% (n = 367) were exposed to high DBI score (≥1). Adjusted multivariate regression analysis revealed no significant association between DBI score and daytime dozing, constipation or falls. After adjusting for confounders (sex, age, level of ID, comorbidities, behaviours that challenge, history of falls), DBI was associated with significantly higher dependence in the Barthel index (P = 0.002).

Conclusions: This is the first time DBI has been described in older adults with ID. Scores were much higher than those observed in the general population and higher scores were associated with higher dependence in Barthel index activities of daily living.

Citing Articles

Dynamic changes in medication burden leading to fall and hospital readmissions in older adults: Toward a strategy for improving risk and managing costs.

Rasu R, Xavier C, Rianon N J Manag Care Spec Pharm. 2025; 31(1):96-100.

PMID: 39745841 PMC: 11695846. DOI: 10.18553/jmcp.2025.31.1.96.


Constipation-associated factors in outpatients with schizophrenia: A multicenter questionnaire survey.

Tazaki T, Yamada H, Sato R, Ishii H, Sugita S, Yanagihara H Neuropsychopharmacol Rep. 2024; 44(3):604-613.

PMID: 38957048 PMC: 11544439. DOI: 10.1002/npr2.12464.


Anticholinergic load: A commonly neglected and preventable risk to cognition during schizophrenia treatment?.

Martinez-Cao C, Garcia-Fernandez A, Gonzalez-Blanco L, Saiz P, Bobes J, Garcia-Portilla M Schizophr Res Cogn. 2024; 37:100317.

PMID: 38745931 PMC: 11092394. DOI: 10.1016/j.scog.2024.100317.


The adverse effects of long-term exposure to anticholinergics among people with intellectual disabilities: a scoping review.

Al Shuhaimi L, Henman M, McCallion P, McCarron M, ODwyer M HRB Open Res. 2023; 5:63.

PMID: 37396688 PMC: 10308137. DOI: 10.12688/hrbopenres.13599.1.


Exposure to anticholinergic and sedative medication is associated with impaired functioning in older people with vertigo, dizziness and balance disorders-Results from the longitudinal multicenter study MobilE-TRA.

Katzenberger B, Koller D, Strobl R, Kisch R, Sanftenberg L, Voigt K Front Pharmacol. 2023; 14:1136757.

PMID: 36937862 PMC: 10020174. DOI: 10.3389/fphar.2023.1136757.


References
1.
Santosh P, Baird G . Psychopharmacotherapy in children and adults with intellectual disability. Lancet. 1999; 354(9174):233-42. DOI: 10.1016/S0140-6736(98)07059-7. View

2.
Vestergaard P, Prieto-Alhambra D, Javaid M, Cooper C . Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose. Osteoporos Int. 2012; 24(2):671-80. PMC: 3658008. DOI: 10.1007/s00198-012-2043-5. View

3.
Weiner D, Hanlon J, Studenski S . Effects of central nervous system polypharmacy on falls liability in community-dwelling elderly. Gerontology. 1998; 44(4):217-21. DOI: 10.1159/000022013. View

4.
Stolker J, Koedoot P, Heerdink E, Leufkens H, Nolen W . Psychotropic drug use in intellectually disabled group-home residents with behavioural problems. Pharmacopsychiatry. 2002; 35(1):19-23. DOI: 10.1055/s-2002-19838. View

5.
Chiba Y, Shimada A, Yoshida F, Keino H, Hasegawa M, Ikari H . Risk of fall for individuals with intellectual disability. Am J Intellect Dev Disabil. 2009; 114(4):225-36. DOI: 10.1352/1944-7558-114.4:225-236. View